Navigation Links
TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R))
Date:1/15/2014

TAIPEI, Jan. 15, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn®) in the Russian Federation, Turkey and other members of the Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, R-Pharm will be responsible for the development, registration and commercialization of nemonoxacin in these territories and assume all associated costs. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones as well as royalties on product sales in the future.

About Nemonoxacin

Nemonoxacin is a novel non-fluorinated quinolone available in both oral and intravenous formulations. In the clinical trials conducted to this point, nemonoxacin has shown activity against drug-resistant bacteria such as methicillin-­resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA as well as quinolone-resistant Streptococcus pneumoniae. TaiGen has completed a multi-center Phase 2 and 3 of the oral formulation in community-acquired pneumonia (CAP) in Taiwan and mainland China and submitted NDA to regulatory authorities in both countries in 2013. In June 2012, TaiGen out-licensed the exclusive rights of mainland China to Zhejiang Medicine. In the U.S., TaiGen has completed two Phase 2 studies, one in CAP and the other in diabetic foot infections (DFI). In December 2013, the U.S. FDA granted nemonoxacin Qualified Infectious Disease Product (QIDP) and Fast Track designation
'/>"/>

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Puma Biotechnology Announces Completion of Private Placement
2. Animal Biotechnology - Technologies, Markets and Companies
3. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
4. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
5. JumpStart Invests $250,000 in Milo Biotechnology
6. Global Biotechnology Industry
7. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
8. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Global Biotechnology Instrumentation Industry
11. Choose New Jersey, Inc. to Tout New Jerseys Life Sciences Hub At Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... 2014 A new report by ... applications and geography) - Size, Share, Global Trends, Company ... Forecast, 2013 - 2020", suggests that the global surgical ... 2020 registering a CAGR of 11.1% from 2014 to ... the electro surgical devices in operative procedures by providing ...
(Date:7/29/2014)... 2014 Philadelphia’s newest entrepreneurial incubation space is ... start. The Innovation Center @3401 , a collaborative effort ... Science Center to help attract and nurture start-up businesses ... 28. , The Innovation Center @3401 (ic@3401), ... Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... of VIA, and,James G. Stewart, senior vice president ... at the Seventh Annual Needham & Company,Biotechnology and ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... systems, today announced that President and,Chief Executive Officer Michael ... company,s business outlook, growth strategy and,recent financial results at ... On Thursday, June 12, the company will present at ...
... 3 Masimo Corporation,(Nasdaq: MASI ), the ... announced,that it is scheduled to present at the ... Ritz Carlton, Laguna Nigel, in Dana Point, CA,on ... Joe E. Kiani, Chairman and,CEO, will be presenting., ...
Cached Biology Technology:Cynosure Announces Schedule of Upcoming Investor Conferences 2Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... brain cells suggests that the effects of a commonly ... are temporary. , The study, published in this week,s ... conducted by biologists at the University of California, San ... in response to concerns, arising from multiple studies on ... general anesthetics may increase their susceptibility to long-term cognitive ...
(Date:7/28/2014)... of the top 10 U.S. cities that have seen ... inconveniences as frequent road closures, overwhelmed storm drains and ... new NOAA technical report. , This nuisance flooding, caused ... U.S. coasts, between 300 and 925 percent since the ... Flood Frequency Changes around the United States, also finds ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3
... difference between a lifeless sack of chemicals and ... they're organized, according to Stanford biophysical chemist Steven ... California-Davis and Lawrence Livermore National Laboratory, he has ... unprecedented resolution-on the order of 100 nanometers, a ...
... million grant from the National Cancer Institute, a Wake Forest ... the effectiveness of a drug that he developed for the ... M.D., Ph.D., pioneered a method to destroy cells of glioblastoma ... is currently being tested in clinical trials and Debinski is ...
... plumage, flamingos are a curiosity of nature. Now a new ... anatomical oddity that helps flamingos eat: erectile tissue. , Flamingos ... shallow water, they bend their necks, tilt their bills upside ... Their large tongue acts like a piston, sucking water into ...
Cached Biology News:With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2Ohio University researchers discover evolutionary oddity in flamingos 2
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
Biology Products: